Rybelsus

Overview

Rybelsus is the oral formulation of semaglutide co-formulated with SNAC (an absorption enhancer) to enable peptide absorption across the gastric mucosa. It is approved for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. It offers needle-free GLP-1 therapy, though with low oral bioavailability (~1%) and strict fasting requirements. It was the first oral GLP-1 peptide; oral semaglutide is now also sold as Wegovy tablets and Ozempic tablets.

Mechanism of Action

Semaglutide peptide absorbed via SNAC carrier technology in the stomach, subsequently binding to GLP-1 receptors systemically to stimulate insulin secretion, inhibit glucagon, and slow gastric emptying.

Clinical Evidence

The PIONEER clinical trial program demonstrated glycemic control comparable to injectable GLP-1s and modest weight loss of ~4.4 kg at the 14 mg dose. PIONEER 6 confirmed cardiovascular safety, and SOUL (9,650 adults with type 2 diabetes and cardiovascular or chronic kidney disease) showed 14% fewer major adverse cardiovascular events than placebo (hazard ratio 0.86) over a median 49.5 months.

Side Effects & Safety

GI adverse events consistent with semaglutide (nausea, abdominal pain, diarrhea), along with the burden of strict administration timing (on an empty stomach in the morning with up to 4 ounces of water, then at least 30 minutes before food, drink or other oral medicines).

FAQ